Failure of Dupilimab With Severe Prurigo Nodularis That Responded Well to Abrocitinib

被引：13

作者：

Vander Does, Ashley ^{[1
,2
]}

Yosipovitch, Gil ^{[1
,2
]}

机构：

[1] Univ Miami, Dr Phillip Frost Dept DermatolMiami Itch Ctr, Miami, FL 33146 USA

[2] Univ Miami, Miami Itch Ctr, Dr Phillip Frost Dept Dermatol, Miami, FL 33146 USA

来源：

DERMATITIS | 2023年 / 34卷 / 06期

关键词：

D O I：

10.1089/derm.2022.0065

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：567 / 567

页数：1

共 5 条

[1] A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications [J].

Agrawal, Diksha ;

Sardana, Kabir ;

Mathachan, Sinu Rose ;

Bhardwaj, Minakshi ;

Ahuja, Arvind ;

Jain, Swasti .

JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (09) :4009-4015

[2] Topical Janus kinase-signal transducers and activators of transcription inhibitor tofacitinib is effective in reducing nonatopic dermatitis chronic itch: A case series [J].

Ju, Teresa ;

Labib, Angelina ;

Vander Does, Ashley ;

Yosipovitch, Gil .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (02) :400-403

[3] Immunotargets and Therapy for Prurigo Nodularis [J].

Labib, Angelina ;

Ju, Teresa ;

Vander Does, Ashley ;

Yosipovitch, Gil .

IMMUNOTARGETS AND THERAPY, 2022, 11 :11-21

[4] Successful treatment of recalcitrant nodular prurigo with tofacitinib [J].

Molloy, O. E. ;

Kearney, N. ;

Byrne, N. ;

Kirby, B. .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2020, 45 (07) :918-920

[5]

Yosipovitch G., EADV C 2022

← 1 →